RIGI and cancer: Koerner et al. [143] recently reported that biodegradable poly (lactic-co-glycolic acid) (PLGA) particles carrying TLR3/RIG-I ligand Riboxxim could potently activate murine and human DCs and elevate tumor-specific CD8+ T cell responses, showing effective anti-cancer effect in preclinical tumor models.